Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | TPH1 | P17752 | 1/20 | 0.30 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533159 | 0.93 | ALOX5AP (0.41) | ALOX5APCYP3A4CYP2C9PTGS1PPARD | |
| SCHEMBL5531949 | 0.86 | ALOX5AP (0.61) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5518293 | 0.83 | ALOX5AP (0.38) | ALOX5APCYP3A4CYP2C9PTGS1PPARD | |
| SCHEMBL3468110 | 0.81 | ALOX5AP (0.39) | ALOX5APCYP3A4CYP2C9PTGS1PPARD | |
| SCHEMBL3468133 | 0.81 | ALOX5AP (0.53) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL3468347 | 0.81 | ALOX5AP (0.40) | ALOX5APCYP3A4CYP2C9PTGS1PPARD | |
| SCHEMBL3468313 | 0.80 | ALOX5AP (0.50) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5535144 | 0.79 | ALOX5AP (0.48) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5532182 | 0.78 | ALOX5AP (0.60) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5523418 | 0.78 | ALOX5AP (0.48) | ALOX5APCYP3A4CYP2C9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885CYP3A4 912/4885CYP2C9 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.